Realgar-induced differentiation is associated with MAPK pathways in HL-60 cells

Cell Biology International

Volumn 32, Issue 12, 2008, Pages 1497-1505

  Wang, Nan ^a   Wang, Li Wen ^b   Gou, Bao Di ^a   Zhang, Tian Lan ^a,b   Wang, Kui ^a  

^a PEKING UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Arsenic sulfide; Differentiation; HL 60; MAPK pathway; Realgar

Indexed keywords

ARSENIC DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL;

ANTIGENS, CD11; ANTINEOPLASTIC AGENTS; ARSENICALS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; HL-60 CELLS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUKEMIA, PROMYELOCYTIC, ACUTE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 3; NANOPARTICLES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA, MESSENGER; SULFIDES;

EID: 56149102360     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2008.08.017     Document Type: Article

References (42)

1. Alessi D.R., Cuenda A., Cohen P., Dudley D.T., and Saltiel A.R. PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo. J Biol Chem 270 (1995) 27489-27494
2. Battle T.E., Roberson M.S., Zhang T., Varvayanis S., and Yen A. Retinoic acid-induced blr1 expression requires RAR-alpha, RXR, and MAPK activation and uses ERK2 but not JNK/SAPK to accelerate cell differentiation. Eur J Cell Biol 80 (2001) 59-67
3. Birnie G.D. The HL60 cell line: a model system for studying human myeloid cell differentiation. Br J Cancer Suppl. 9 (1998) 41-45
4. Chang L., and Karin M. Mammalian MAP kinase signaling cascades. Nature 410 (2001) 37-40
5. Degos L. The history of acute promyelocytic leukaemia. Br J Haematol 122 (2003) 539-553
6. Deng Y., Xu H.B., Huang K., Yang X., Xie C., and Wu J. Size effects of realgar particles on apoptosis in a human umbilical vein endothelial cell line: ECV-304. Pharmacol Res 44 (2001) 513-518
7. Drayson M.T., Michell R.H., Durham J., and Brown G. Cell proliferation and CD11b expression are controlled independently during HL60 cell differentiation initiated by 1,25α-dihydroxyvitamin D3 or all-trans-retinoic acid. Exp Cell Res 266 (2001) 126-134
8. English J.M., and Cobb M.H. Pharmaceutical inhibitors of MAPK pathways. Trends Pharmacol Sci 23 (2000) 40-45
9. Evens A.M., Tallman M.S., and Gartenhaus R.B. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res 28 (2004) 891-900
10. Frantz B., Klatt T., Pang M., Parsons J., Rolando A., Williams H., et al. The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry 37 (1998) 13846-13853
11. Goldstein D.M., and Gabriel T. Pathway to the clinic: inhibition of p38 MAP kinase. A review of ten chemotypes selected for development. Curr Top Med Chem 5 (2005) 1017-1029
12. Huang S.Y., Chang C.S., Tang J.L., Tien H.F., Kuo T.L., Huang S.F., et al. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol 103 (1998) 1092-1110
13. Ishii Y., Sakai S., and Honma Y. Pyridinyl imidazole inhibitor SB203580 activates p44/42 mitogen-activated protein kinase and induced the differentiation of human myeloid leukemia cells. Leuk Res 25 (2001) 813-820
14. Ji Y., Kutne A., Verstuyf A., Verlinden L., and Studzinski G.P. Derivatives of vitamins D2 and D3 activate three MAPK pathways and upregulate pRb expression in differentiating HL60 cells. Cell Cycle 1 (2002) 410-415
15. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy - from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 1754 (2005) 253-262
16. Kim S.H., Oh S.M., and Kim T.S. Induction of human leukemia HL-60 cell differentiation via a PKC/ERK pathway by helenalin, a pseudoguainolide sesquiterpene lactone. Eur J Pharmacol 511 (2005) 89-97
17. Lau A., Li M., Xie R., He Q.Y., and Chiu J.F. Opposed arsenite-induced signalling pathways promote cell proliferation or apoptosis in cultured lung cells. Carcinogenesis 25 (2004) 21-25
18. Lee J.C., Kumar S., Griswold D.E., Underwood D.C., Votta B.J., and Adams J.L. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 47 (2000) 185-201
19. Lenoble V., Deluchat V., Serpaud B., and Bollinger J. Arsenite oxidation and arsenate determination by the molybdene blue method. Talanta 61 (2003) 267-276
20. Lu D.P., Qiu J.Y., Jiang B., Wang Q., Liu K.Y., Liu Y.R., et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 99 (2002) 3136-3143
21. Mayer R.J., and Callahan J.F. p38 MAP kinase inhibitors: a future therapy for inflammatory diseases. Drug Disc Today 3 (2006) 49-54
22. Miller Jr. W.H., Schipper H.M., Lee J.S., Singer J., and Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 62 (2002) 3893-3903
23. Miranda M.B., McGuire T.F., and Johnson D.E. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines. Leukemia 16 (2002) 683-692
24. Potin S., Bertoglio J., and Breard J. Involvement of a Rho-ROCK-JNK pathway in arsenic trioxide-induced apoptosis in chronic myelogenous leukemia cells. FEBS Lett 581 (2007) 118-124
25. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 4 (2004) 372-377
26. Sanz M.A. Treatment of acute promyelocytic leukemia. Hematology (2006) 147-155
27. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89 (1997) 3354-3360
28. Soignet S.L., Frankel S.R., Douer D., Tallman M.S., Kantarjian H., Calleja E., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19 (2001) 3852-3860
29. Suzuki K., Adachi R., Hirayama A., Watanabe H., Otani S., Watanabe Y., et al. Indirubin, a Chinese anti-leukaemia drug, promotes neutrophilic differentiation of human myelocytic leukeamia HL-60 cells. Br J Haematol 130 (2005) 681-690
30. Underwood D.C., Osborn R.R., Bochnowicz S., Webb E.F., Rieman D.J., Lee J.C., et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 279 (2000) 895-902
31. Wang Q., Harrison J.S., Uskokovic M., Kutner A., and Studzinski G.P. Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant. Leukemia 19 (2005) 1812-1817
32. Wang Q., Wang X., and Studzinski G.P. Jun N-terminal kinase pathway enhances signaling of monocytic differentiation of human leukemia cells induced by 1,25-dihydroxyvitamin D3. J Cell Biochem 89 (2003) 1087-1101
33. Wang X., Rao J., and Studzinski G.P. Inhibition of p38 MAP kinase activity up-regulates multiple MAP kinase pathways and potentiates 1,25-dihydroxy vitamin D3-induced differentiation of human leukemia HL60 cells. Exp Cell Res 258 (2000) 425-437
34. Wang X., and Studzinski P.G. Activation of extra cellular signal-regulated kinases (ERKs) defines the first phase of 1,25-dihydroxyvitamin D3-induced differentiation of HL-60 cells. J Cell Biochem 80 (2001) 471-482
35. Wang X.B., Gao H.Y., Hou B.L., Huang J., Xi R.G., and Wu L.J. Nanoparticle realgar powders induce apoptosis in U937 cells through caspase MAPK and mitochondrial pathways. Arch Pharm Res 30 (2007) 653-658
36. Wang Z., and Chen Z. Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia. Oncology 1 (2000) 101-106
37. Waxman S., and Anderson K.C. History of the development of arsenic derivatives in cancer therapy. Oncologist 6 Suppl. 2 (2001) 3-10
38. Wu J.Z., and Ho P.C. Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding. Eur J Pharm Sci 29 (2006) 35-44
39. Ye H.Q., Gan L., Yang X.L., and Xu H.B. Membrane toxicity accounts for apoptosis induced by realgar nanoparticles in promyelocytic leukemia HL-60 cells. Biol Trace Elem Res 103 (2004) 117-132
40. Yen A., Robertson M.S., and Varvayanis S. Retinoic acid selectively activates the ERK2 but not JNK/SAPK or p38MAP kinases when inducing myeloid differentiation. In Vitro Cell Dev Biol Anim 35 (1999) 527-532
41. 4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood 104 (2004) 4219-4225
42. Zhang T.D., Cheng G.Q., Wang Z.G., Wang Z.Y., Chen S.J., and Chen Z. Arsenic trioxide, a therapeutic agent for APL. Oncogene 20 (2001) 7146-7153